Incretin-based therapies in prediabetes: Current evidence and future perspectives
about
Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis.Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications.Oral formulation of DPP-4 inhibitor plus Quercetin improves metabolic homeostasis in type 1 diabetic rats
P2860
Incretin-based therapies in prediabetes: Current evidence and future perspectives
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@ast
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@en
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@nl
type
label
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@ast
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@en
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@nl
prefLabel
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@ast
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@en
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@nl
P2860
P356
P1476
Incretin-based therapies in prediabetes: Current evidence and future perspectives
@en
P2093
Georgios S Papaetis
P2860
P304
P356
10.4239/WJD.V5.I6.817
P577
2014-12-01T00:00:00Z